MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.01
-5.58
-21.81%
Pre Market: 19.60 -0.41 -2.05% 08:50 05/06 EDT
OPEN
18.39
PREV CLOSE
25.59
HIGH
20.44
LOW
18.01
VOLUME
3.35K
TURNOVER
--
52 WEEK HIGH
53.73
52 WEEK LOW
18.01
MARKET CAP
563.40M
P/E (TTM)
-3.6503
1D
5D
1M
3M
1Y
5Y
Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May. Event:Bank of America 2021 Healthcare ConferenceDa...
GlobeNewswire · 14m ago
70 Biggest Movers From Yesterday
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd.
Benzinga · 3h ago
Esperion’s bull case is off the table: Stifel
Having lost more than a fifth of value so far, Esperion Therapeutics ([[ESPR]] -21.8%) is on course to mark its biggest one-day loss in nearly two years after its Q1
Seekingalpha · 16h ago
Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines
Benzinga · 17h ago
Mid-Afternoon Market Update: Dow Surges 180 Points; Big 5 Sporting Goods Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 0.53% to 34,313.88 while the NASDAQ rose 0.18% to 13,658.26. The S&P also rose, gaining 0.41% to 4,181.69.
Benzinga · 17h ago
ADMP, BGFV, ATNX and ESPR among midday movers
Gainers: Regional Health Properties (RHE) +124%.SunLink Health Systems (SSY) +66%.Nemaura Medical (NMRD) +60%.Chiasma (CHMA) +48%.Athenex (ATNX) +31%.Caesarstone (CSTE) +30%.Hayward (HAYW) +28%.Altisource Portfolio Solutions (ASPS) +26%.Big 5 Sporting Good...
Seekingalpha · 20h ago
Mid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results
Midway through trading Wednesday, the Dow traded up 0.09% to 34,162.34 while the NASDAQ rose 0.53% to 13,705.72. The S&P also rose, gaining 0.30% to 4,177.13.
Benzinga · 20h ago
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 64.9% to $7.75 after the company reported an order for 200,000 sugarBEAT sensors.
Benzinga · 20h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ESPR. Analyze the recent business situations of Esperion Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ESPR stock price target is 51.64 with a high estimate of 134.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 261
Institutional Holdings: 37.34M
% Owned: 132.63%
Shares Outstanding: 28.16M
TypeInstitutionsShares
Increased
50
4.39M
New
16
241.27K
Decreased
51
4.15M
Sold Out
26
1.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
President/Chief Executive Officer/Director
Timothy Mayleben
Chief Financial Officer
Richard Bartram
Chief Operating Officer
Sheldon Koenig
Other
Ashley Hall
Lead Director/Independent Director
Nicole Vitullo
Director
Jeffrey Berkowitz
Independent Director
Alan Fuhrman
Independent Director
Antonio Gotto
Independent Director
Daniel Janney
Independent Director
Mark McGovern
Independent Director
Jay Shepard
Independent Director
Tracy Woody
No Data
About ESPR
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.